No CrossRef data available.
Article contents
Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD
Published online by Cambridge University Press: 10 January 2022
Abstract
Subcutaneous treprostinil is commonly used to improve idiopathic pulmonary arterial hypertension in children. However, its effectiveness has not been reported in trisomy 21. We report the case of 9-year-old boy in trisomy 21 with CHD-pulmonary artery hypertension after surgical correction of CHD. Haemodynamics and exercise capacity dramatically improved with a transition from oral selexipag to subcutaneous treprostinil.
- Type
- Brief Report
- Information
- Copyright
- © The Author(s), 2022. Published by Cambridge University Press